Detalhe da pesquisa
1.
Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic, Omalizumab, in Severe Asthma in Adults: Results of the SoMOSA Study.
Am J Respir Crit Care Med
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635834
2.
Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
Allergy
; 79(5): 1195-1207, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164813
3.
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
J Allergy Clin Immunol
; 151(3): 747-755, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36538979
4.
Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.
J Allergy Clin Immunol
; 151(5): 1269-1276, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36740144
5.
Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses.
Respir Res
; 24(1): 305, 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38057814
6.
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
J Allergy Clin Immunol
; 150(5): 1097-1105.e12, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772597
7.
Genome-wide association study of asthma, total IgE, and lung function in a cohort of Peruvian children.
J Allergy Clin Immunol
; 148(6): 1493-1504, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33713768
8.
Socioeconomic status is of higher importance than air pollution and environmental factors in childhood asthma prevalence in Urban Australia.
J Allergy Clin Immunol
; 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38830511
9.
Editorial comment on "Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)".
Pediatr Allergy Immunol
; 35(4): e14128, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38646955
10.
Editorial comments on "Asthma and rhinitis control in adolescents and young adults: A real-world MASK-air study".
Pediatr Allergy Immunol
; 35(5): e14134, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702900
11.
Incidence of adverse events prompting switching between biologics among adults with asthma: A retrospective cohort study.
Allergy
; 78(4): 1116-1119, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36286487
12.
Editorial comment on "Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain".
Pediatr Allergy Immunol
; 34(7): e13980, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492923
13.
From preschool wheezing to asthma: Determinants.
Pediatr Allergy Immunol
; 34(10): e14040, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37877851
14.
Editorial comment on: "Developing a prediction model of children's asthma risk using population-based family history health records".
Pediatr Allergy Immunol
; 34(12): e14063, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146114
15.
Pediatric Allergy and Immunology (PAI) is for polishing with artificial intelligence, but careful use.
Pediatr Allergy Immunol
; 34(9): e14023, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37747752
16.
Prevalence of anaphylaxis among adults admitted to critical care for severe asthma exacerbation.
Emerg Med J
; 35(10): 623-625, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093380
17.
Mentoring into productivity during fellowship: A working tripartite model.
J Allergy Clin Immunol
; 147(5): 1627-1628, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667478
18.
Addressing disparities in biologic drug development in the United States.
J Allergy Clin Immunol
; 148(5): 1154-1156, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34530019
19.
The development and evaluation of an evidence-based guideline programme to improve care in a paediatric emergency department.
Emerg Med J
; 33(2): 109-17, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26150121
20.
Severe asthma in the US population and eligibility for mAb therapy.
J Allergy Clin Immunol
; 145(4): 1295-1297.e6, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31866437